Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9310951 | 0.82 | KMT2A (0.66) | MEN1KMT2AGFERCDK2HPGD | |
| SCHEMBL25800533 | 0.78 | CCNE2 (0.56) | MEN1KMT2AGFERCCNE2CCNE1 | |
| SCHEMBL2210096 | 0.78 | MEN1 (1.00) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL1396186 | 0.77 | KMT2A (0.59) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL13181182 | 0.73 | KMT2A (0.66) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL9367057 | 0.72 | NOTUM (0.55) | MEN1KMT2ACCNE2CCNE1CDK2 | |
| SCHEMBL3669381 | 0.71 | MEN1 (0.55) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL1102295 | 0.71 | MEN1 (0.55) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL15662150 | 0.70 | MEN1 (0.47) | MEN1KMT2AGFERHPGDTSHR | |
| SCHEMBL27829670 | 0.70 | KMT2A (0.72) | MEN1KMT2AGFERHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| CN-101405282-A | Aurora kinase modulators and methods of use | AMGEN INC (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | MEN1 635/4885KMT2A 741/4885GFER 4507/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | MEN1 768/4885KMT2A 771/4885GFER 4472/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | MEN1 635/4885KMT2A 741/4885GFER 4507/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | MEN1 635/4885KMT2A 741/4885GFER 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.